We serve Chemical Name:methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate CAS:1381944-72-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate
CAS.NO:1381944-72-4
Synonyms:methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate
Molecular Formula:C16H12F2O4
Molecular Weight:306.26100
HS Code:2917399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:52.60000
Exact Mass:306.07000
LogP:3.20500
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate Use and application,methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate technical grade,usp/ep/jp grade.
Related News: Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees. methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate manufacturer Hong Kong confirmed its 14th coronavirus case late Saturday. The patient, an 80-year-old man, had traveled for a few hours to mainland China in early January, and later spent several days on a cruise ship in Japan with more than 3,000 passengers and employees. methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate supplier Since inception in 2004, ICIG has acquired 15 businesses, all of which have origins in major global chemical or pharmaceutical corporations and are independently managed. methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate vendor When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate factory The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. methyl 2-fluoro-3-(4-fluoro-3-methoxycarbonylphenyl)benzoate factory The vaccine also proved safe during the two-year trial, in which eleven doses were administered to randomly chosen patients with mild dementia. People who received the vaccine, known as AADvac1, experienced about the same numbers of side effects and adverse events as those who were given a placebo.
